Thomas E. Witzig

750 papers receiving 33.7k citations

Thomas E. Witzig's Hit Papers

Rituximab for IgG4-related disease: a prospective, open-label trial 2015 · 464 citations
4640+8+16Years since publication50010001.5k

Peers

Thomas E. Witzig
Comparison fields: 5 of 162
  • Hematology 9.0k
  • Pathology and Forensic Medicine 12.5k
  • Genetics 7.4k
  • Oncology 11.1k
  • Immunology 5.2k
Replace Wolfgang Hiddemann with:
Wolfgang Hiddemann Germany
Bruce D. Cheson United States
John F. Seymour Australia
L. Jeffrey Medeiros United States
Gilles Salles France
Stephen M. Ansell United States
Jamés O. Armitage United States
Alessandro Rambaldi Italy
Bertrand Coiffier France
William G. Wierda United States
Thomas E. Witzig relative to Wolfgang Hiddemann Germany Wolfgang Hiddemann's profile →
Citations per field
00.5×1.5×
Wolfgang Hiddemann · 1×
Citations per year

Countries citing papers authored by Thomas E. Witzig

Since Specialization
Citations

This map shows the geographic impact of Thomas E. Witzig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Witzig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Witzig more than expected).

Fields of papers citing papers by Thomas E. Witzig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Witzig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Witzig. The network helps show where Thomas E. Witzig may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas E. Witzig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas E. Witzig Line = papers co-authored together Thomas E. Witzig links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 782 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Hit paper breakdown →
20031658
2
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
Hit paper breakdown →
2002844
3
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
Hit paper breakdown →
2004646
4 2003496
5 2005486
6 1997476
7 2002466
8
Rituximab for IgG4-related disease: a prospective, open-label trial
Hit paper breakdown →
2015464
9 1999431
10 2002413
11 2005403
12 2006354
13 2011301
14 2013271
15
Prognostic value of bone marrow angiogenesis in multiple myeloma.
2000269
16 2012268
17 2004268
18 2014268
19 2010254
20 2009245

About Thomas E. Witzig

Thomas E. Witzig is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Molecular Biology and Hematology, having authored 782 papers that have together received 34.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (423 papers), Chronic Lymphocytic Leukemia Research (236 papers), Multiple Myeloma Research and Treatments (131 papers), Viral-associated cancers and disorders (75 papers), Monoclonal and Polyclonal Antibodies Research (51 papers), CNS Lymphoma Diagnosis and Treatment (43 papers), CAR-T cell therapy research (42 papers) and Immune Cell Function and Interaction (41 papers). The work is most often cited by research in Hematology (9.0k citations), Pathology and Forensic Medicine (12.5k citations), Genetics (7.4k citations), Oncology (11.1k citations) and Immunology (5.2k citations). Thomas E. Witzig has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Philip R. Greipp, S. Vincent Rajkumar, Stephen M. Ansell, Robert A. Kyle, Martha Q. Lacy, Morie A. Gertz, John A. Lust, Angela Dispenzieri, Rafaël Fonseca and Thomas M. Habermann. Their work appears in journals such as Blood, Journal of Clinical Oncology, American Journal of Hematology, British Journal of Haematology and Blood Cancer Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact